The UPCI Chemical Biology Facility (ChBF) has emerged from an innovative UPCI-supported pilot project to become a new Shared Facility. The overall goal ofthe ChBF is to ensure that UPCI members have access to the most modern chemical biology reagents, instrumentation, and personnel, which will enable them to identify unique chemical probes and potential anticancer leads for further optimization. The ChBF will provide high quality support services to UPCI researchers for: 1) high throughput screening (HTS) and high content screening (HCS) assay design, development, validation, and implementation, 2) small molecule and siRNA library distribution, 3) lead characterization and optimization, and 4) data analysis. A component ofthe ChBF's service will include supplying high quality, professional access to multiple automated liquid handlers for use in 96- and 384-well plate formats, detectors, large chemical libraries, siRNA libraries, chemical informatics, chemical analysis, analog acquisition, and sophisticated data analysis software. The ChBF will collaborate with UPCI faculty, staff, and trainees in developing and conducting cancer-relevant, cell-free and cell-based HTS and HCS assays. Training will be offered either on an individual or group basis depending on the perceived need or formal requests for training. Availability of ChBF resources will be disseminated through posts on the UPCI website, emails to UPCI members, and annual workshops, seminars, and poster presentations at the UPCI retreat. The ChBF is especially interested in promoting innovative assays at UPCI. Therefore, it will encourage the development and implementation of challenging cancer-related assays. In particular, the ChBF will promote novel HCS assays focused on targets that have traditionally been considered "undruggable" as an innovative component of its activity within UPCI. The ChBF creates a starting point for the identification of unique chemical probes and lead structures for potential new therapies for all of UPCI's Programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-26
Application #
8705410
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$123,232
Indirect Cost
$41,711
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Zhang, Xuan; Bresee, Jamee; Fields, Gregg B et al. (2014) Near-infrared triple-helical peptide with quenched fluorophores for optical imaging of MMP-2 and MMP-9 proteolytic activity in vivo. Bioorg Med Chem Lett 24:3786-90
Oborski, Matthew J; Demirci, Emre; Laymon, Charles M et al. (2014) Assessment of early therapy response with 18F-FLT PET in glioblastoma multiforme. Clin Nucl Med 39:e431-2
Gross, Neil D; Bauman, Julie E; Gooding, William E et al. (2014) Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clin Cancer Res 20:3289-98
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Yang, Liangchun; Xie, Min; Yang, Minghua et al. (2014) PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. Nat Commun 5:4436
Sun, Xiaofang; Tang, Daolin (2014) HMGB1-dependent and -independent autophagy. Autophagy 10:1873-6
Pollock, Sheri L; Rush, Elizabeth A; Redner, Robert L (2014) NPM-RAR, not the RAR-NPM reciprocal t(5;17)(q35;q21) acute promyelocytic leukemia fusion protein, inhibits myeloid differentiation. Leuk Lymphoma 55:1383-7
Ng, Yuen-Keng; Lee, Jia-Ying; Supko, Kathryn M et al. (2014) Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res 24:207-18
Popovtzer, Aron; Normolle, Daniel; Worden, Francis P et al. (2014) Phase I trial of radiotherapy concurrent with twice-weekly gemcitabine for head and neck cancer: translation from preclinical investigations aiming to improve the therapeutic ratio. Transl Oncol 7:479-83
Peterson, Lanell M; Kurland, Brenda F; Schubert, Erin K et al. (2014) A phase 2 study of 16*-[18F]-fluoro-17*-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Mol Imaging Biol 16:431-40

Showing the most recent 10 out of 463 publications